An interventional study of Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment. in Glaucoma and Ocular Hypertension, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 94 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 8th largest by planned enrollment of the 364 interventional ones that give a count, is one of 29 that started in 2025, is one of 163 with no phase, reaches primary completion later than 84 of the 93 other live ones, and was the 428th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Tavo Biotherapeutics · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 30–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
490 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 88 · Phase 3 51 · Phase 4 66
First in 1976; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 358 that completed or were terminated, 138 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 490 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 3 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
34 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants may have glaucoma, and/or other eye conditions (diabetic retinopathy, cataract, visual acuity impairment). The glaucoma screening will incorporate use of an artificial intelligence (AI)-assisted screening tool. This project is called AI-RONA. The main questions it aims to answer are:
Participants will:
Federally Qualified Health Center (FQHC) clinics are excellent candidate clinics for eye disease screening programs for adults, including glaucoma and also other glaucoma associated diseases (GAD), diabetic retinopathy, cataract and refractive error. These clinics are safety-net primary health care clinics in the United States designed to serve medically underserved areas and populations. The physician will provide services regardless of the patient's ability to pay, using a sliding-scale fee based on the ability to pay. Over half the patient population at FQHCs nationally is Black or Hispanic, with 82% of patients uninsured or federally insured. While FQHCs provide primary medical care in many health domains, one domain that is not adequately addressed by FQHC clinics is eye care. A recent report by the National Academies of Science, Engineering and Medicine indicated that primary eye care services (through optometrists or ophthalmologists) are rarely available at FQHC clinics; the report provided an estimate that less than 3% of FQHC patients actually receive vision care services at these clinics, representing 0.89% of FQHC clinic visits.
The screening methods used in this protocol are a modified version of our prior imaging-based ophthalmologist guided telemedicine screening protocol utilized in the previous CDC- funded Alabama Screening and Intervention for Glaucoma and eye Health through Telemedicine (AL-SIGHT) study. In AL-SIGHT we used a telemedicine program to screen for glaucoma in 3 FQHCs located in a low-income, under-resourced region of the state with a high proportion of Black residents. Just as we did in AL-SIGHT, investigators in the current protocol will target screening only for those FQHC patients at-risk for glaucoma. The eligibility definition for screening in the current project is listed under Eligibility.
After screening, patients with a screening diagnosis of GAD, diabetic retinopathy, cataract, or visual acuity impairment will be referred for an in-person follow-up exam by an ophthalmologist or optometrist located in the FQHC clinic's region. In the investigators' previous project, participants had excellent adherence to the follow-up appointment with the optometrist or ophthalmology at a rate of 76.7% of patients attending follow-up. Thus, Investigators are hopeful that in the current project they will also have this high level of adherence.
There are two major differences between our previous project (AL-SIGHT) and the current project AI-RONA. In AL-SIGHT, we used research staff members to do the screening at the FQHCs. In AI-RONA investigators will now use implementation science to do the screening. This means that investigators will train the FQHC clinic staff to do the screening after a detailed training and certification program. A second way AI-RONA differs from AL-SIGHT is that investigators will use an AI-assisted, remote screening algorithm to generate the screening results for glaucoma. Investigators will also focus on both the effectiveness of the program (disease detection, rate of referrals) and primary care providers (PCPs) and patients' attitudes about AI-RONA. The latter will be achieved by administering a questionnaire to PCPs and to participants about their satisfaction with the screening program.
The AI approaches to be deployed for AI-RONA have been previously developed and extensively tested by the AI-researchers at the University of California, San Diego, who are also investigators in AI-RONA. It was found that glaucoma testing using AI based on retinal images taken of patients' eyes lead to clinician-level accuracy. These AI methodologies have been tested on diverse populations and publicly available datasets to facilitate their accuracy.
The eye screen protocol that investigators are using includes the following. All assessments are performed on each eye separately: (1) retinal imaging including fundus photography and optical coherence tomography (OCT), (2) visual acuity measurement, (3) refractive error measurement.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eight FQHCs will participate in this project. Four FQHCs will implement a glaucoma screening protocol and a protocol for detecting diabetic retinopathy, cataract, and visual acuity impairment, while the other four will be standard of care without the above screening protocol.
Other: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.
Primary care provider asks participants if they are having symptoms or problems with their eyes or vision.
Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
Rate of participants where the glaucoma screening protocol leads to a screening diagnosis of glaucoma
Primary care provider will make a screening diagnosis of glaucoma associated disease based on the results of the screening
Time frame: up to 2-3 days
Rate of participants who decide to attend the follow up exam by optometrist or ophthalmologist
If diagnosed with any of the above conditions, and primary car provider recommends follow-up care with an optometrist or ophthalmologist, whether participant actually attends the exam
Time frame: up to 4 months
Rate of participants where the screening protocol leads to a screening diagnosis of cataract, diabetic retinopathy, or visual acuity impairment
Based on results of screening, the primary care provider will be able to make a screening diagnosis of cataract, diabetic retinopathy or visual acuity impairment
Time frame: up to 2-3 days
Compare cost of screening program in FQHC to the cost of an ophthalmologist or optometrist guided assessment
Compare the cost of AI based interventions relying on optic disc photos alone, OCT alone, both imaging modalities, and imaging with standard vision tests performed by an ophthalmologist or optometrist guided program
Time frame: up to 4 years
Rate of primary care provider who state they agree with intervention acceptability, appropriateness, and feasibility
Whether the primary care provider agrees with the eye screening program per the Acceptability of Intervention Measure, Intervention Appropriateness Measure, and Feasibility of Intervention Measure; scores range from 16 to 80 with higher scores meaning more agreement
Time frame: up to 6 months
Rate of participants who state they agree with the acceptability of the screening intervention
Whether the participant agrees with the acceptability of eye screening per Post AI-RONA Screening questionnaire; scores range from 9 to 45 with higher scores meaning more agreement
Time frame: up to 1 day
Plan to share: Yes — de-identified data will be shared.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: September 29, 2029
Access criteria: Scientists who work in the field of glaucoma screening and other types of eye screening will be able to access the supporting information described above. They can access this information by contacting the principal investigator.
Data sharing details ↗ · www.uab.edu
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 47 months is above that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →